Clinical drug development company Noxopharm
(ASX:NOX) has released DARRT-1 study clinical data.
The Company says the “DARRT program delivers strong anti-cancer response in 47 per cent of men with late-stage prostate cancer”.
An independent oncologist, Professor Paul de Souza, has confirmed the significance of this high response rate.
The company hopes that the “promising new therapy” will meet a “major unmet need in prostate cancer”.
The planned adaptive design Phase 2 study is expected to be the final step before gaining marketing approval.
Shares in Noxopharm
(ASX:NOX) are trading 1.61 per cent higher at 32 cents.
